Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks.

2 Sep 2009

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

Skin disease psoriasis associated with cardiovascular disease and increased mortality

The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death, according to a report in the June issue of Archives of Dermatology.

16 Jun 2009

Abbott and AstraZeneca to co-promote Trilipix (fenofibric acid)

Abbot and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

5 Jun 2009

High blood pressure, diabetes and increased carotid artery wall thickness means increased risk of stroke

Increased carotid artery wall thickness (CAWT), which can cause heart attack and stroke in many patients, is significantly related to diabetes and hypertension, according to a study performed at A.O.U. in Cagliari Sardegna, Italy (Chairman, Professor Giorgio Mallarini).

23 Apr 2009

Too much sugar is bad, but which sugar is worse: Fructose or glucose?

In 2005, the average American consumed 64kg of added sugar, a sizeable proportion of which came through drinking soft drinks.

21 Apr 2009

In lab supplements of lipoic acid lower triglyceride levels

Studies done with laboratory rats suggest that supplementation of their diet with lipoic acid had a significant effect in lowering triglycerides, which along with cholesterol levels and blood pressure are one of the key risk factors in cardiovascular disease.

30 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

11 new genes linked to LDL, HDL cholesterols and triglycerides

A new study uncovers 11 gene variants associated with three blood lipids measured to determine cardiovascular disease risk: low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) and triglycerides.

15 Dec 2008

Metabolex announces positive results from phase 2 trial of MBX-8025

The Phase 2 study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor(R)), over an 8-week treatment period.

19 Nov 2008

Initiative by world-recognized specialists in heart disease and diabetes to reduce residual vascular risk

Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Melanin shows potential as new drug target for obesity

As millions of Americans gear up for the Thanksgiving holiday, a new research report published online in The FASEB Journal, may provide some relief for those leery of having a second helping.

29 Oct 2008

New devices used to reduce arterial occlusions, provide cardiac support

Research results highlighting three new devices used to reduce blockages in peripheral and coronary arteries and to provide cardiac support will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

Major study aims for new approaches to cardiovascular disease management

The Consortium for Southeastern Hypertension Control (COSEHC), headquartered at Wake Forest University Baptist Medical Center, is launching a major five-year study designed to update current guidelines for treating cardiovascular diseases, improve disease management and reduce heart attacks and strokes in the Southeast.

24 Sep 2008

Issues on cholesterol: diet, statins and genetics

Genetic lipoprotein disorders are frequently seen in patients with premature coronary artery disease (CAD). An example of strong genetic predisposition is the disorder: familial hypercholesterolemia, where a single gene defect (the low density lipoprotein receptor) contributes to most of the familial expression of CAD.

1 Sep 2008

DES in diabetic patients

The issue of using or not using DES in patients with diabetes will be debated between Professor Wijns, who discourages DES and Professor Silber, who feels that they should be used.

31 Aug 2008